Zhou, Biao
Zhou, Runhong
Tang, Bingjie http://orcid.org/0000-0002-2900-0392
Chan, Jasper Fuk-Woo http://orcid.org/0000-0001-6336-6657
Luo, Mengxiao
Peng, Qiaoli
Yuan, Shuofeng
Liu, Hang http://orcid.org/0000-0002-6176-3963
Mok, Bobo Wing-Yee
Chen, Bohao
Wang, Pui
Poon, Vincent Kwok-Man http://orcid.org/0000-0002-7737-8912
Chu, Hin http://orcid.org/0000-0003-2855-9837
Chan, Chris Chung-Sing http://orcid.org/0000-0001-7089-4829
Tsang, Jessica Oi-Ling
Chan, Chris Chun-Yiu
Au, Ka-Kit
Man, Hiu-On
Lu, Lu
To, Kelvin Kai-Wang http://orcid.org/0000-0002-1921-5824
Chen, Honglin http://orcid.org/0000-0001-5108-8338
Yuen, Kwok-Yung http://orcid.org/0000-0002-2083-1552
Dang, Shangyu http://orcid.org/0000-0001-9141-1865
Chen, Zhiwei http://orcid.org/0000-0002-4511-2888
Article History
Received: 19 January 2022
Accepted: 7 June 2022
First Online: 23 June 2022
Competing interests
: The authors declare no conflicts of interest except for a provisional patent application filed for human monoclonal antibodies generated in our laboratory with Z.C., B.Z., and R.Z. as the co-inventers. J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited. The funding sources had no role in study design, data collection, analysis or interpretation, or writing of the report.